Tests extra cancer scanning in people with unexplained stroke
Tests a PET scan added to usual care to find hidden cancer.
Plain-language title generated from the registry record
Registry title: Intensive Cancer Screening After Cryptogenic Stroke
Key facts
- Where
- Calgary, Montreal, and Ottawa, CanadaSee the 3 sites
Where in Canada
- Calgary Foothills Medical CentreCalgary, CanadaNot yet recruiting
- Centre Hospitalier de l'Université de MontréalMontreal, CanadaTaking people
- The Ottawa HospitalOttawa, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ottawa Hospital Research Institute
- Trial code
- NCT05733416
- Record updated
- 15 October 2026
- Original description
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.Read full original descriptionShow less
Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO) Pilot Randomized Trial
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Inclusion: adults ≥18 years; presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke); patient or delegate willing and able to provide informed consent.
Exclusion: active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin); contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes).